首页> 外国专利> METHOD FOR PREDICTING TUMOUR RESISTANCE TO TETHEGETH THERAPY OF CETUXIMAB IN PATIENTS WITH PLANE-CELLULAR LANGUAGE OF LANGUAGE AND MULTIDISAL BOTTOM OF THE PTA

METHOD FOR PREDICTING TUMOUR RESISTANCE TO TETHEGETH THERAPY OF CETUXIMAB IN PATIENTS WITH PLANE-CELLULAR LANGUAGE OF LANGUAGE AND MULTIDISAL BOTTOM OF THE PTA

机译:PTA的多细胞底部语言和平面细胞语言预测患者抗西妥昔单抗叶突治疗的抗肿瘤方法

摘要

FIELD: medicine.;SUBSTANCE: invention is a method for predicting tumour resistance to target therapy of cetuximab in patients with squamous cell carcinoma of the tongue and oral mucosa including a blood test, characterized in that two days before the initiation of a chemo-chemotherapy treatment with the inclusion of targeted cetuximab therapy in a patient with squamous cell carcinoma of the tongue And the mucosal bottom is determined by EGF, sEGFR, then the ratio of EGF/sEGFR is calculated and at a value of this ratio between 55.3-66.9 it is predicted that there is no resistance against Plaques to cetuximab therapy, and with the value of this indicator within 92.6-117.8 predict the presence of tumour resistance to cetuximab therapy.;EFFECT: early prognosis of tumour resistance to targeted therapy with cetuximab.;2 ex, 1 tbl
机译:舌鳞状细胞癌和口腔黏膜鳞状细胞癌患者的抗肿瘤治疗方法本发明是预测舌癌和口腔粘膜鳞状细胞癌患者对西妥昔单抗靶向治疗的抗药性的方法,包括验血,其特征在于开始化学化疗前两天舌鳞状细胞癌患者接受西妥昔单抗靶向治疗,并通过EGF,sEGFR确定粘膜底部,然后计算EGF / sEGFR的比值,该比值在55.3-66.9之间,预计对斑块对西妥昔单抗治疗无耐药性,且该指标的值在92.6-117.8之间可预测肿瘤对西妥昔单抗治疗的耐药性;效果:肿瘤对西妥昔单抗靶向治疗的早期预后; 2例如,1汤匙

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号